Board Change • May 20
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. No independent directors (5 non-independent directors). Non-Executive Director Natalya Jurcheshin was the last director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Announcement • Mar 27
Myeco Group Ltd announced that it expects to receive AUD 2 million in funding Myeco Group Ltd has announced a private placement to issue Unsecured Series Two Convertible Note of the company to raise gross proceeds of AUD 2,000,000 on March 27, 2026. The transaction involves the investor participation of professional and sophisticated investors will be issued under the Company’s 15% placement capacity pursuant to ASX. The notes are 100% convertible into ordinary shares of the company at a conversion price value of AUD 0.019 per share and carry interest rate of 10.5%. The conversion price will be at a 15% discount to the VWAP over 14 trading days preceding the date of the conversion notice. The transaction is subject to approval of the board of directors of the company. The transaction is expected to close on March 31, 2026. Board Change • Dec 24
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Non-Executive Director Natalya Jurcheshin was the last director to join the board, commencing their role in 2023. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Sep 11
Myeco Group Ltd, Annual General Meeting, Nov 13, 2025 Myeco Group Ltd, Annual General Meeting, Nov 13, 2025. Announcement • Apr 23
MyEco Group Ltd Provides an Update on Its Operational Restructure Initiatives MyEco Group Ltd. provided an update on its operational restructure initiatives. On 10 February 2025, the Company announced a strategic review of its manufacturing and production operations to support its record MyEco® branded sales growth more cost effectively, and to reposition the cost base of its manufacturing and production supply chain. The following initiatives from the operational restructure are all expected to be completed by June 2025: The ability to scale production capacity through strategic partnerships with high- end converters in south-east Asia, to reduce production costs, increase redundancy of supply chains, and increase flexibility to meet demand in different geographies - Reduced cost from the rationalisation of manufacturing assets in Malaysia - Relocation of larger pilot production equipment from Melbourne to the company's commercial plant in Nanjing, China to reduce costs for new product trials and realise efficiencies in upscaling to commercial production. Relocation of the company's head office and product development centre to lower-cost premises within Melbourne to reduce both rent and overheads The implementation of these initiatives is expected to deliver annual fixed cost savings of circa $2.5 million to $3.0 million commencing in the first quarter of fiscal year 2026. They will streamline MyEco Group's operations and scale production more efficiently with an aim to improve product margins, while minimising the requirement for capital investment. The company's fully integrated approach, utilising internal assets and key partnerships, positions MyEco Group to meet increasing demand in a cost-effective manner while maintaining the high-quality standards that the brand is known for. Announcement • Sep 19
SECOS Group Limited, Annual General Meeting, Nov 14, 2024 SECOS Group Limited, Annual General Meeting, Nov 14, 2024. Reported Earnings • Aug 23
Full year 2024 earnings released: AU$0.016 loss per share (vs AU$0.012 loss in FY 2023) Full year 2024 results: AU$0.016 loss per share (further deteriorated from AU$0.012 loss in FY 2023). Revenue: AU$14.4m (down 37% from FY 2023). Net loss: AU$9.42m (loss widened 40% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 25 percentage points per year, which is a significant difference in performance. New Risk • Aug 15
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of Australian stocks, typically moving 12% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (AU$13.7m market cap, or US$9.09m). Minor Risk Share price has been volatile over the past 3 months (12% average weekly change). New Risk • Jun 21
New major risk - Market cap size The company's market capitalization is less than US$10m. Market cap: AU$14.9m (US$9.92m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Market cap is less than US$10m (AU$14.9m market cap, or US$9.92m). Announcement • Sep 26
SECOS Group Limited, Annual General Meeting, Nov 17, 2023 SECOS Group Limited, Annual General Meeting, Nov 17, 2023, at 10:00 AUS Eastern Standard Time. Reported Earnings • Aug 25
Full year 2023 earnings released: AU$0.012 loss per share (vs AU$0.006 loss in FY 2022) Full year 2023 results: AU$0.012 loss per share (further deteriorated from AU$0.006 loss in FY 2022). Revenue: AU$22.8m (down 26% from FY 2022). Net loss: AU$6.75m (loss widened 119% from FY 2022). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 56 percentage points per year, which is a significant difference in performance. New Risk • Aug 18
New minor risk - Financial data availability The company's latest financial reports are more than 6 months old. Last reported fiscal period ended December 2022. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks Latest financial reports are more than 6 months old (reported December 2022 fiscal period end). Shareholders have been diluted in the past year (11% increase in shares outstanding). Market cap is less than US$100m (AU$35.0m market cap, or US$22.4m). Announcement • May 25
SECOS Group Limited Appoints Natalya Jurcheshin as Non-Executive Director SECOS Group Limited announced the appointment of experienced company director and senior leader Natalya Jurcheshin to its Board as a Non-Executive Director. Ms Jurcheshin brings over twenty years' experience spanning finance, operations and strategy throughout Australia, North America, Ukraine and Russia in professional services, private and public companies, start-ups, and SMEs. Ms. Jurcheshin is a Non-Executive Director of Adacel Technologies Limited where she is the Chair of the Audit & Risk Management Committee and Remuneration Committee. She is a former CFO, Head of Operations and Company Secretary of Circadian Technologies Limited (renamed Opthea Limited) and is a qualified chartered accountant. Ms Jurcheshin has leadership experience in finance and accounting, risk management, strategy, operations, audit and assurance services and board roles. Her diverse commercial experience includes other senior roles with Antisense Therapeutics Limited Melbourne Symphony Orchestra, Arthur Andersen (now part of Ernst & Young) and NEISS Group Pty Ltd. Announcement • Feb 20
SECOS Group Limited Launches New 95% Certified Recycled MyEcoBag The Board of SECOS Group Limited provided the market with an update on the launch of its new 95% Certified Recycled MyEco range of products. SECOS Group Limited launches a new recycled MyEco bin liner range produced from 95% soft-plastic Post-Consumer Waste which has been certified to meet Global Recycle Standards for recycling content, chain of custody, social and environmental practices, and chemical restrictions. Unlike many recycled products that are not produced from Post- Consumer Waste, MyEc recycled products offer a genuine recycling solution for soft plastics without compromising quality. The products will be offered for sale as part of the Group's MyEco range of products and will target the growing recycled product market segment, to reduce the amount of virgin plastic finding its way into environment and to reduce petroleum consumption and CO2 emissions. SECOS Group, an Australian company, will produce the MyEco 95% Recycled range in the Company's Asian manufacturing plants. The expanded range further aligns SECOS insupporting the Australian Government's environmental policy of "Reuse, Recycle or Compost" as stated in the Australian National Plastic Plan and mirrors policy in many other key markets around the world in the fight to reducing the amount of single use plastic in environment. Reported Earnings • Feb 17
First half 2023 earnings released: AU$0.005 loss per share (vs AU$0.001 loss in 1H 2022) First half 2023 results: AU$0.005 loss per share (further deteriorated from AU$0.001 loss in 1H 2022). Revenue: AU$11.8m (down 23% from 1H 2022). Net loss: AU$2.48m (loss widened 214% from 1H 2022). Revenue is forecast to grow 34% p.a. on average during the next 2 years, compared to a 8.2% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has remained flat, which means it is well ahead of earnings. Board Change • Nov 17
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 3 experienced directors. 1 highly experienced director. No independent directors (4 non-independent directors). Non-Executive Director Jim Walsh was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 27
Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.005 profit in FY 2021) Full year 2022 results: AU$0.006 loss per share (down from AU$0.005 profit in FY 2021). Revenue: AU$31.0m (up 3.2% from FY 2021). Net loss: AU$3.09m (down 219% from profit in FY 2021). Over the next year, revenue is forecast to grow 28%, compared to a 12% growth forecast for the Chemicals industry in Australia. Over the last 3 years on average, earnings per share has increased by 90% per year but the company’s share price has only increased by 37% per year, which means it is significantly lagging earnings growth. Board Change • Jul 12
No independent directors No new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 1 highly experienced director. No independent directors (5 non-independent directors). Non-Executive Director Jim Walsh was the last director to join the board, commencing their role in 2018. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of independent directors. Insufficient board refreshment. Reported Earnings • Aug 14
Full year 2021 earnings released The company reported a strong full year result with improved earnings, revenues and profit margins. Full year 2021 results: Revenue: AU$30.1m (up 43% from FY 2020). Net income: AU$2.59m (up AU$3.78m from FY 2020). Profit margin: 8.6% (up from net loss in FY 2020). The move to profitability was driven by higher revenue. Breakeven Date Change • Jun 30
Forecast breakeven pushed back to 2022 The analyst covering SECOS Group previously expected the company to break even in 2021. New forecast suggests the company will make a profit of AU$5.70m in 2022. Average annual earnings growth of 103% is required to achieve expected profit on schedule. Recent Insider Transactions • Mar 04
Executive Director recently bought AU$307k worth of stock On the 2nd of March, Stephen Walters bought around 1m shares on-market at roughly AU$0.31 per share. This was the largest purchase by an insider in the last 3 months. Despite this recent purchase, insiders have collectively sold AU$636k more in shares than they bought in the last 12 months. Analyst Estimate Surprise Post Earnings • Feb 23
Revenue beats expectations Revenue exceeded analyst estimates by 3.4%. Over the next year, revenue is forecast to grow 50%, compared to a 15% growth forecast for the Chemicals industry in Australia. Is New 90 Day High Low • Feb 09
New 90-day high: AU$0.34 The company is up 113% from its price of AU$0.16 on 11 November 2020. The Australian market is up 10.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.50 per share. Recent Insider Transactions • Feb 05
Executive Chairman recently bought AU$60k worth of stock On the 4th of February, Richard Tegoni bought around 200k shares on-market at roughly AU$0.30 per share. This was the largest purchase by an insider in the last 3 months. This was Richard's only on-market trade for the last 12 months. Is New 90 Day High Low • Jan 21
New 90-day high: AU$0.24 The company is up 53% from its price of AU$0.16 on 23 October 2020. The Australian market is up 11% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 10.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.49 per share. Is New 90 Day High Low • Jan 06
New 90-day high: AU$0.21 The company is up 26% from its price of AU$0.17 on 09 October 2020. The Australian market is up 12% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is down 1.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.50 per share. Is New 90 Day High Low • Nov 19
New 90-day high: AU$0.20 The company is up 24% from its price of AU$0.17 on 21 August 2020. The Australian market is up 7.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is flat over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is AU$0.46 per share. 